Open-label Study on Treatment of Primary Aldosteronism With Everolimus
NCT03174171
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
12
Enrollment
OTHER
Sponsor class
Conditions
Primary Aldosteronism
Interventions
DRUG:
Everolimus 0.75 mg
Sponsor
University Hospital, Basel, Switzerland